Invention Grant
US08808684B2 Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
有权
表皮生长因子受体（EGFR）以及用于腺病毒相关病毒6型（AAV6）转导的方法
- Patent Title: Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
- Patent Title (中): 表皮生长因子受体（EGFR）以及用于腺病毒相关病毒6型（AAV6）转导的方法
-
Application No.: US12879142Application Date: 2010-09-10
-
Publication No.: US08808684B2Publication Date: 2014-08-19
- Inventor: John Chiorini , Michael Schmidt , Melodie L. Weller
- Applicant: John Chiorini , Michael Schmidt , Melodie L. Weller
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Leydig, Voit & Mayer
- Main IPC: A01N63/00
- IPC: A01N63/00 ; A61K39/23 ; C12N15/86 ; C12N15/00 ; A61K48/00 ; C07K14/71
Abstract:
Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.
Public/Granted literature
Information query
